Objective: The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear.
Methods: In this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group.
Results: While the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67-73 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20-23 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after-not before-was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination.
Conclusion: Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1-3 days before vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556747 | PMC |
| http://dx.doi.org/10.1136/rmdopen-2022-002639 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study.
Vaccines (Basel)
September 2024
Department of Medicine, McGill University, Montreal, QC H3A 0E9, Canada.
Article Synopsis
- - SARS-CoV-2 is still a major cause of death in North America, and this study examines how methotrexate and tumor necrosis factor inhibitors (TNFi) affect vaccine responses in patients with immune-mediated inflammatory diseases (IMID).
- - Researchers collected and analyzed serum samples from 479 adults with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) across Canada to evaluate neutralization responses to COVID-19 vaccination.
- - The results indicated that both methotrexate and TNFi independently reduced the ability to neutralize the virus, underscoring the need for careful vaccination strategies as COVID-19 remains widespread.
Evaluation of Vaccine Strategies among Healthcare Workers during COVID-19 Omicron Outbreak in Taiwan.
Vaccines (Basel)
September 2024
Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Article Synopsis
- This study evaluated the safety and immune response of various COVID-19 vaccines among healthcare workers in Taiwan during the Omicron variant outbreak, comparing their effectiveness.
- Conducted from March 2021 to July 2023, the research involved 710 healthcare workers who received different vaccines, with blood samples taken to measure antibody levels and record side effects.
- Results showed that mRNA vaccines like Moderna offered the highest initial antibody levels and effectiveness, while regular booster doses significantly boosted immunity and reduced COVID-19 cases among workers.
Article Synopsis
- - COVID-19 continues to pose risks to health, including long COVID, necessitating ongoing evaluation of vaccines and immunity against different variants of the virus.
- - A study analyzed immunity levels from vaccines, past infections, and hybrid immunity from December 2021 to August 2023 in Czechia, finding that recent booster vaccination significantly protects against severe COVID-19, while older vaccinations achieve less protection.
- - The study concludes that while vaccination is still effective in preventing severe COVID-19, its effects diminish over time, emphasizing the need for booster shots, and that prior immunity offers limited protection against long COVID after infection.
Nosocomial Outbreak of SARS-CoV-2 in a Hospital Ward during the Omicron Variant-Dominant Wave with a Review of the Relevant Literature.
Jpn J Infect Dis
September 2024
Department of Infectious Diseases, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan.
Clusters of nosocomial coronavirus disease 2019 (COVID-19) have been reported globally during the recent pandemic. Unfortunately, these clusters negatively affect inpatient morbidity, mortality, and hospital functioning. Using epidemiological data and whole-genome sequencing (WGS) of SARS-CoV-2, this study investigated the outbreak of COVID-19 at a university hospital.
View Article and Find Full Text PDFPseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage.
PLoS Pathog
May 2024
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Pairwise compatibility between virus and host proteins can dictate the outcome of infection. During transmission, both inter- and intraspecies variabilities in receptor protein sequences can impact cell susceptibility. Many viruses possess mutable viral entry proteins and the patterns of host compatibility can shift as the viral protein sequence changes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!